TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today gastroenterology roundup published October 22, 2026, highlighted research associating antibiotic use in childhood and young adulthood with higher odds of irritable bowel syndrome, alongside joint American Gastroenterological Association and AASLD guidelines for primary biliary cholangitis. The report also covered liver-transplant preparation research and several clinical trials; it did not provide detailed methods, guideline recommendations or trial results for every item.
A MedPage Today gastroenterology roundup published October 22, 2026, highlighted research linking antibiotic use during childhood and young adulthood with higher odds of irritable bowel syndrome (IBS) and reported that the American Gastroenterological Association and the American Association for the Study of Liver Diseases had issued joint guidelines for primary biliary cholangitis (PBC). The report summarizes a range of developments, but does not supply the detailed study methods, effect sizes or guideline recommendations needed to assess their full clinical implications.
The IBS finding was presented at the annual United European Gastroenterology (UEG) Week meeting. According to the roundup, researchers found an association between antibiotic use in childhood and young adulthood and increased odds of IBS. The report does not state how large the increase was, which antibiotics or exposure periods were examined, or whether the research established any cause-and-effect relationship. The finding is an association, not evidence from this summary that antibiotics cause IBS.
The roundup also reported that the AGA and AASLD published joint PBC management guidelines in the journal Hepatology. It did not describe the recommendations, their evidence grading, or whether they revise specific earlier guidance. The organizations’ publication marks a relevant clinical update for a chronic liver disease, but readers and clinicians would need the full guideline to determine what care changes, if any, are advised.
Other items included research suggesting an individualized exercise and dietary prehabilitation program may improve the chances that liver-transplant candidates survive long enough to receive an organ. At UEG Week, Gilead Sciences reported promising phase II results for investigational ulcerative-colitis drug emvistegrast, while AbbVie presented a phase IIa Crohn’s disease trial of ABBV-466. The roundup says ABBV-466 had higher endoscopic remission rates than either anti-IL-23 or anti-α4β7 treatment alone, but provides no rates or study details. These are early-stage findings, not proof of regulatory approval or routine clinical benefit.
What the IBS and PBC Updates Could Change
The antibiotic finding may help researchers investigate how early-life exposures relate to later digestive symptoms, but the brief report does not establish that avoiding or changing antibiotic treatment would prevent IBS. Antibiotics can be prescribed for important infections; treatment decisions should be made with a qualified clinician rather than based on an association alone.
The joint PBC guidelines may provide clinicians with shared recommendations from two major US professional societies. Their practical effect cannot be judged from the roundup alone: the specific advice, intended patient groups and any changes to existing practice are not described. For people living with PBC, the full guidance and advice from their treating team matter more than the headline summary.
The transplant-prehabilitation research and the drug-trial reports also point to active work across liver and inflammatory bowel disease care. Yet the roundup’s limited details mean readers should treat these as research developments, not established treatment options. Trial phase, study design and measured outcomes all affect how much confidence can be placed in early findings.
As an affiliate, we earn on qualifying purchases.
The Studies Behind the Roundup
The source is a short news-and-commentary roundup by Ian Ingram, MedPage Today’s managing editor, dated October 22, 2026. It groups reports from UEG Week with guideline publication and other gastroenterology and hepatology news. The IBS result is described as research presented at the meeting; the PBC development is described as joint guidelines published in Hepatology.
The source also noted several separate developments: Cosmo said a placebo-controlled phase II trial of rifamycin 1% topical gel met its primary endpoint in mild-to-moderate distal ulcerative colitis and ulcerative proctitis; the International Organization for the Study of Inflammatory Bowel Disease reviewed updated treatment targets; and a scoping review supported consideration of population screening for celiac disease. These items are not findings from one coordinated study and should not be read as a single change in gastroenterology practice.
The roundup included consumer-health coverage of fiber-rich “constipation cookies” and whether blowing bubbles on the toilet might help constipation. It also reported that a controversial hepatitis B vaccine trial in Guinea-Bissau had been halted, citing the lead researcher, and that South African authorities were linking a gastrointestinal illness affecting more than 500 people to poor water quality in two cities. These are separate stories and do not establish a connection to the IBS research or PBC guidance.
“Research presented at the annual United European Gastroenterology (UEG) Week meeting linked antibiotic use in childhood and young adulthood to increased odds of irritable bowel syndrome (IBS).”
— MedPage Today roundup, describing the UEG Week research
Study Details Still Missing
The roundup does not provide the IBS study’s sample size, antibiotic exposure definitions, statistical estimates, participant characteristics or adjustment for other factors. It is also unclear from the summary whether the research was published in a peer-reviewed journal or whether the association persisted after accounting for potential confounders. Without those details, the size and reliability of the reported relationship cannot be assessed.
For the PBC guidelines, the summary gives no recommendations, publication date beyond the roundup’s date, evidence review or explanation of how the guidance compares with prior advice. For the prehabilitation study and drug trials, it omits key design information, participant numbers, numerical outcomes and safety findings. The roundup characterizes some results as promising or potentially beneficial, but does not establish long-term outcomes or routine-care effectiveness.
Full Guidance and Trial Data
The next useful step for readers seeking clinical detail is to consult the full AGA-AASLD PBC guideline and the original IBS research report, including its methods and results. Those sources would clarify the recommendations and the strength and limits of the antibiotic association. The roundup itself does not announce a follow-up date or say when additional IBS findings will be published.
For emvistegrast, ABBV-466 and rifamycin gel, subsequent trial publications or company and conference updates may provide fuller efficacy and safety data. The research descriptions do not establish whether or when later-stage trials will begin. Until more information is available, the findings should be understood as reported research developments rather than approved new care standards.
Key Questions
Did the report show that antibiotics cause IBS?
No. It reported that research presented at UEG Week linked antibiotic use in childhood and young adulthood with higher odds of IBS. The summary does not establish causation or provide the methods needed to assess the association.
What changed in primary biliary cholangitis care?
The roundup reported that the AGA and AASLD issued joint management guidelines, published in Hepatology. It did not list the recommendations, so the specific implications for treatment cannot be determined from this report.
Are the ulcerative colitis and Crohn’s disease drugs available as treatments?
The items describe phase II and phase IIa research. The roundup does not say the investigational drugs are approved or available for routine care, and it does not provide enough data to judge their benefits and risks.
What did the transplant-prehabilitation research find?
The report said an individualized program combining exercise and dietary changes may improve the chances that candidates survive to receive a liver transplant. It did not provide the study size, effect estimate or enough detail to establish how the program should be used.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
